Concepts (313)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Low Back Pain | 12 | 2020 | 41 | 2.640 |
Why?
|
| Analgesics, Opioid | 14 | 2022 | 251 | 1.710 |
Why?
|
| Pain, Postoperative | 10 | 2019 | 198 | 1.610 |
Why?
|
| Opioid-Related Disorders | 7 | 2025 | 68 | 1.510 |
Why?
|
| Autonomic Nerve Block | 3 | 2015 | 11 | 1.290 |
Why?
|
| Primary Health Care | 8 | 2025 | 232 | 1.160 |
Why?
|
| Pain Measurement | 18 | 2020 | 339 | 1.120 |
Why?
|
| Analgesics | 9 | 2018 | 111 | 0.990 |
Why?
|
| Health Policy | 2 | 2025 | 89 | 0.970 |
Why?
|
| Perioperative Care | 3 | 2019 | 51 | 0.950 |
Why?
|
| Electronic Health Records | 5 | 2025 | 179 | 0.890 |
Why?
|
| Medicaid | 1 | 2025 | 101 | 0.870 |
Why?
|
| Sacroiliac Joint | 3 | 2014 | 12 | 0.860 |
Why?
|
| Insurance Coverage | 1 | 2025 | 80 | 0.860 |
Why?
|
| Midazolam | 2 | 2014 | 11 | 0.850 |
Why?
|
| Diagnostic Techniques and Procedures | 2 | 2014 | 6 | 0.840 |
Why?
|
| Conscious Sedation | 2 | 2014 | 24 | 0.840 |
Why?
|
| Anesthetics, Intravenous | 2 | 2014 | 18 | 0.840 |
Why?
|
| Humans | 62 | 2025 | 32262 | 0.840 |
Why?
|
| Fentanyl | 2 | 2014 | 33 | 0.840 |
Why?
|
| Complex Regional Pain Syndromes | 2 | 2014 | 24 | 0.830 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 230 | 0.810 |
Why?
|
| Obesity | 5 | 2014 | 1111 | 0.800 |
Why?
|
| Pain | 7 | 2012 | 302 | 0.790 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2008 | 82 | 0.740 |
Why?
|
| Osteoarthritis, Knee | 1 | 2023 | 71 | 0.740 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2025 | 63 | 0.740 |
Why?
|
| Fear | 3 | 2014 | 42 | 0.600 |
Why?
|
| Buprenorphine | 1 | 2019 | 13 | 0.580 |
Why?
|
| Treatment Outcome | 15 | 2023 | 3408 | 0.580 |
Why?
|
| Male | 40 | 2025 | 19429 | 0.560 |
Why?
|
| Zygapophyseal Joint | 2 | 2007 | 3 | 0.530 |
Why?
|
| Resistance Training | 2 | 2014 | 58 | 0.510 |
Why?
|
| Anesthetics, Local | 3 | 2015 | 85 | 0.500 |
Why?
|
| Neuralgia | 2 | 2015 | 46 | 0.490 |
Why?
|
| Cyclohexanecarboxylic Acids | 3 | 2006 | 20 | 0.490 |
Why?
|
| Amines | 3 | 2006 | 23 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 395 | 0.470 |
Why?
|
| Denervation | 4 | 2008 | 12 | 0.470 |
Why?
|
| Middle Aged | 23 | 2025 | 11837 | 0.460 |
Why?
|
| Stellate Ganglion | 1 | 2015 | 1 | 0.450 |
Why?
|
| Ventricular Fibrillation | 1 | 2015 | 6 | 0.450 |
Why?
|
| Medulla Oblongata | 5 | 2007 | 51 | 0.440 |
Why?
|
| Disability Evaluation | 3 | 2014 | 241 | 0.440 |
Why?
|
| Receptors, Opioid, mu | 4 | 2007 | 36 | 0.430 |
Why?
|
| Phantom Limb | 1 | 2014 | 4 | 0.430 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 316 | 0.420 |
Why?
|
| Female | 29 | 2025 | 19935 | 0.410 |
Why?
|
| Receptors, Opioid, delta | 5 | 2007 | 15 | 0.410 |
Why?
|
| United States | 9 | 2025 | 4068 | 0.400 |
Why?
|
| Schools, Medical | 1 | 2014 | 43 | 0.400 |
Why?
|
| Exercise Therapy | 2 | 2014 | 249 | 0.400 |
Why?
|
| Anesthesiology | 1 | 2014 | 46 | 0.390 |
Why?
|
| Faculty, Medical | 1 | 2014 | 76 | 0.380 |
Why?
|
| Diabetic Neuropathies | 2 | 2013 | 28 | 0.380 |
Why?
|
| Adult | 16 | 2025 | 9252 | 0.370 |
Why?
|
| Health Behavior | 1 | 2013 | 213 | 0.360 |
Why?
|
| Spinal Cord | 4 | 2004 | 137 | 0.360 |
Why?
|
| Nociceptors | 6 | 2004 | 36 | 0.360 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 167 | 0.360 |
Why?
|
| Osteoarthritis | 1 | 2012 | 73 | 0.350 |
Why?
|
| Postoperative Care | 3 | 2019 | 79 | 0.340 |
Why?
|
| Walking | 4 | 2014 | 199 | 0.300 |
Why?
|
| Anemia, Sickle Cell | 2 | 2020 | 42 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2017 | 544 | 0.290 |
Why?
|
| Societies, Medical | 3 | 2018 | 153 | 0.290 |
Why?
|
| Aged | 14 | 2018 | 10249 | 0.290 |
Why?
|
| Catheter Ablation | 2 | 2008 | 113 | 0.290 |
Why?
|
| Pain Threshold | 2 | 2008 | 93 | 0.280 |
Why?
|
| Ketamine | 2 | 2018 | 20 | 0.280 |
Why?
|
| Inflammation | 4 | 2007 | 507 | 0.280 |
Why?
|
| Hyperalgesia | 4 | 2007 | 83 | 0.270 |
Why?
|
| Patient Selection | 2 | 2022 | 272 | 0.270 |
Why?
|
| Spinal Diseases | 1 | 2007 | 21 | 0.270 |
Why?
|
| Risk Factors | 9 | 2019 | 3933 | 0.260 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 3 | 2007 | 18 | 0.260 |
Why?
|
| Cervical Vertebrae | 1 | 2007 | 49 | 0.260 |
Why?
|
| Orthopedic Procedures | 1 | 2007 | 89 | 0.250 |
Why?
|
| Ganglia, Spinal | 2 | 2006 | 59 | 0.250 |
Why?
|
| Oligopeptides | 4 | 2007 | 49 | 0.250 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 65 | 0.240 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 3893 | 0.240 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 129 | 0.230 |
Why?
|
| Analgesia | 2 | 2016 | 29 | 0.230 |
Why?
|
| Illinois | 1 | 2025 | 10 | 0.230 |
Why?
|
| Texas | 1 | 2025 | 41 | 0.230 |
Why?
|
| North Carolina | 2 | 2025 | 1300 | 0.220 |
Why?
|
| Physical Endurance | 3 | 2013 | 40 | 0.220 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2007 | 897 | 0.220 |
Why?
|
| Nerve Block | 3 | 2012 | 57 | 0.210 |
Why?
|
| Gait | 3 | 2014 | 120 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Radiosurgery | 1 | 2007 | 355 | 0.210 |
Why?
|
| Enkephalins | 2 | 2001 | 11 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.200 |
Why?
|
| Brain | 3 | 2019 | 966 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 180 | 0.200 |
Why?
|
| Efferent Pathways | 1 | 2003 | 10 | 0.190 |
Why?
|
| Algorithms | 2 | 2017 | 536 | 0.190 |
Why?
|
| Rats | 9 | 2007 | 1895 | 0.190 |
Why?
|
| Receptors, Opioid | 1 | 2003 | 14 | 0.190 |
Why?
|
| Injections, Spinal | 3 | 2016 | 119 | 0.190 |
Why?
|
| Naproxen | 1 | 2002 | 7 | 0.190 |
Why?
|
| Acetates | 1 | 2002 | 14 | 0.190 |
Why?
|
| Research Design | 2 | 2017 | 316 | 0.190 |
Why?
|
| Muscle Strength | 2 | 2013 | 135 | 0.180 |
Why?
|
| Knee Joint | 1 | 2023 | 127 | 0.180 |
Why?
|
| Consensus | 5 | 2019 | 87 | 0.180 |
Why?
|
| Neurons | 2 | 2003 | 486 | 0.180 |
Why?
|
| Anesthesia, Conduction | 2 | 2018 | 24 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Hematology | 1 | 2020 | 8 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 880 | 0.160 |
Why?
|
| Animals | 12 | 2010 | 8196 | 0.160 |
Why?
|
| Body Mass Index | 3 | 2013 | 863 | 0.150 |
Why?
|
| Lower Extremity | 1 | 2020 | 99 | 0.150 |
Why?
|
| Periaqueductal Gray | 1 | 2019 | 2 | 0.150 |
Why?
|
| User-Computer Interface | 1 | 2019 | 54 | 0.150 |
Why?
|
| Neoplasms | 1 | 2025 | 757 | 0.140 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 15 | 0.130 |
Why?
|
| Classification | 1 | 2017 | 1 | 0.130 |
Why?
|
| Analgesia, Epidural | 2 | 2010 | 48 | 0.130 |
Why?
|
| Microinjections | 4 | 2001 | 39 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2017 | 39 | 0.130 |
Why?
|
| Medical Informatics | 1 | 2016 | 26 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2016 | 120 | 0.120 |
Why?
|
| Lumbar Vertebrae | 2 | 2007 | 93 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 83 | 0.120 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 95 | 0.120 |
Why?
|
| Placebos | 1 | 2015 | 68 | 0.120 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 12 | 0.110 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 212 | 0.110 |
Why?
|
| Neurosurgical Procedures | 1 | 2016 | 93 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 72 | 0.110 |
Why?
|
| Sympathectomy | 1 | 2015 | 23 | 0.110 |
Why?
|
| Young Adult | 3 | 2019 | 2643 | 0.110 |
Why?
|
| Volleyball | 1 | 2015 | 1 | 0.110 |
Why?
|
| Terminology as Topic | 3 | 2019 | 68 | 0.110 |
Why?
|
| Family Practice | 1 | 2015 | 49 | 0.110 |
Why?
|
| Electric Countershock | 1 | 2015 | 18 | 0.110 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2008 | 26 | 0.110 |
Why?
|
| Drug Synergism | 4 | 2007 | 66 | 0.110 |
Why?
|
| Soccer | 1 | 2015 | 18 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2015 | 3609 | 0.110 |
Why?
|
| Overweight | 2 | 2013 | 252 | 0.110 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 276 | 0.110 |
Why?
|
| Brain Concussion | 1 | 2015 | 41 | 0.110 |
Why?
|
| Spinal Nerves | 1 | 2015 | 68 | 0.110 |
Why?
|
| Qualitative Research | 3 | 2020 | 179 | 0.110 |
Why?
|
| Injections, Intra-Articular | 1 | 2014 | 15 | 0.100 |
Why?
|
| False Positive Reactions | 1 | 2014 | 27 | 0.100 |
Why?
|
| Efficiency | 1 | 2014 | 17 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 158 | 0.100 |
Why?
|
| Joints | 1 | 2013 | 12 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 245 | 0.100 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2013 | 6 | 0.100 |
Why?
|
| Baseball | 1 | 2015 | 48 | 0.100 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2013 | 13 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2013 | 72 | 0.100 |
Why?
|
| Time Factors | 5 | 2019 | 2203 | 0.100 |
Why?
|
| Affect | 1 | 2013 | 75 | 0.100 |
Why?
|
| Phobic Disorders | 1 | 2013 | 10 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2013 | 413 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2014 | 184 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2013 | 52 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2013 | 123 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 132 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2019 | 1423 | 0.090 |
Why?
|
| Celiac Plexus | 1 | 2012 | 3 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2014 | 367 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 551 | 0.090 |
Why?
|
| Incidence | 3 | 2019 | 1241 | 0.090 |
Why?
|
| Mobility Limitation | 1 | 2013 | 208 | 0.090 |
Why?
|
| Adolescent | 4 | 2019 | 3509 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 131 | 0.080 |
Why?
|
| Behavior, Addictive | 1 | 2010 | 40 | 0.080 |
Why?
|
| Checklist | 1 | 2010 | 39 | 0.080 |
Why?
|
| Diet | 1 | 2012 | 383 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2019 | 44 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 520 | 0.070 |
Why?
|
| Epidural Space | 1 | 2009 | 8 | 0.070 |
Why?
|
| Steroids | 1 | 2009 | 35 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2013 | 273 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 1211 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2018 | 97 | 0.070 |
Why?
|
| HIV Infections | 1 | 2013 | 450 | 0.070 |
Why?
|
| Neck Pain | 1 | 2007 | 5 | 0.070 |
Why?
|
| Radiculopathy | 1 | 2007 | 5 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2008 | 187 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 43 | 0.060 |
Why?
|
| Hindlimb | 3 | 2007 | 53 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 170 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2008 | 173 | 0.060 |
Why?
|
| Forecasting | 1 | 2007 | 144 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 116 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 129 | 0.060 |
Why?
|
| Nortriptyline | 1 | 2006 | 2 | 0.060 |
Why?
|
| Carbamazepine | 1 | 2006 | 4 | 0.060 |
Why?
|
| Reaction Time | 2 | 2007 | 123 | 0.060 |
Why?
|
| Thoracotomy | 1 | 2006 | 19 | 0.060 |
Why?
|
| Fluoroscopy | 1 | 2006 | 35 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 716 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2006 | 58 | 0.060 |
Why?
|
| Mastectomy | 1 | 2006 | 59 | 0.060 |
Why?
|
| Prevalence | 1 | 2008 | 955 | 0.060 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2003 | 35 | 0.060 |
Why?
|
| Urban Population | 1 | 2025 | 91 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 1081 | 0.050 |
Why?
|
| Registries | 1 | 2025 | 294 | 0.050 |
Why?
|
| Rural Population | 1 | 2025 | 216 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 79 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 854 | 0.050 |
Why?
|
| Calcium | 2 | 2002 | 339 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 242 | 0.050 |
Why?
|
| Receptors, GABA | 1 | 2003 | 7 | 0.050 |
Why?
|
| Serotonin Antagonists | 1 | 2003 | 9 | 0.050 |
Why?
|
| GABA Antagonists | 1 | 2003 | 14 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 183 | 0.050 |
Why?
|
| Medicare | 1 | 2004 | 218 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2003 | 10 | 0.050 |
Why?
|
| Quality of Life | 1 | 2008 | 968 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2003 | 86 | 0.050 |
Why?
|
| Narcotics | 1 | 2003 | 32 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 15 | 0.050 |
Why?
|
| Research Subjects | 1 | 2022 | 19 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2002 | 63 | 0.050 |
Why?
|
| Exercise Test | 2 | 2013 | 218 | 0.050 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2001 | 4 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 75 | 0.040 |
Why?
|
| Chemokines | 1 | 2001 | 34 | 0.040 |
Why?
|
| Benzeneacetamides | 1 | 2001 | 3 | 0.040 |
Why?
|
| Somatostatin | 1 | 2001 | 11 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2001 | 16 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 756 | 0.040 |
Why?
|
| Naltrexone | 1 | 2001 | 23 | 0.040 |
Why?
|
| Indiana | 1 | 2020 | 26 | 0.040 |
Why?
|
| Peptides | 1 | 2001 | 127 | 0.040 |
Why?
|
| Skin Temperature | 1 | 2000 | 16 | 0.040 |
Why?
|
| Age Factors | 2 | 2013 | 1178 | 0.040 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 1999 | 35 | 0.040 |
Why?
|
| Child | 2 | 2020 | 2430 | 0.040 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 1 | 1999 | 6 | 0.040 |
Why?
|
| Norepinephrine | 1 | 1999 | 101 | 0.040 |
Why?
|
| Rest | 1 | 2019 | 49 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2013 | 1839 | 0.040 |
Why?
|
| Logistic Models | 2 | 2015 | 743 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2019 | 112 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2019 | 190 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2001 | 415 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2012 | 553 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2020 | 160 | 0.030 |
Why?
|
| Nerve Net | 1 | 2019 | 137 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 66 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 148 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2016 | 2315 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 4 | 0.030 |
Why?
|
| Decision Making | 1 | 2018 | 189 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 77 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 30 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 247 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 169 | 0.030 |
Why?
|
| Sports | 1 | 2015 | 43 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1478 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 312 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 179 | 0.020 |
Why?
|
| Self Concept | 1 | 2013 | 45 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2008 | 2238 | 0.020 |
Why?
|
| African Americans | 1 | 2019 | 1335 | 0.020 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 72 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 246 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 16 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 70 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 854 | 0.020 |
Why?
|
| Injections, Epidural | 1 | 2009 | 8 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2009 | 11 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2010 | 140 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 2007 | 3 | 0.020 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2007 | 35 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2007 | 109 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2007 | 42 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 75 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 358 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2007 | 566 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2004 | 20 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2004 | 42 | 0.010 |
Why?
|
| Pneumonia | 1 | 2004 | 62 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 455 | 0.010 |
Why?
|
| Peripheral Nerves | 1 | 2004 | 60 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2004 | 124 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 650 | 0.010 |
Why?
|
| Prognosis | 1 | 2007 | 1529 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 3 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2001 | 11 | 0.010 |
Why?
|
| Receptors, CCR4 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Bradykinin | 1 | 2001 | 12 | 0.010 |
Why?
|
| Substance P | 1 | 2001 | 22 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 11 | 0.010 |
Why?
|
| Capsaicin | 1 | 2001 | 31 | 0.010 |
Why?
|
| Tail | 1 | 2001 | 5 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2001 | 71 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 52 | 0.010 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2001 | 33 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2001 | 81 | 0.010 |
Why?
|
| Neurons, Afferent | 1 | 2001 | 64 | 0.010 |
Why?
|
| Yohimbine | 1 | 1999 | 7 | 0.010 |
Why?
|
| Dexmedetomidine | 1 | 1999 | 12 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 499 | 0.010 |
Why?
|
| Anesthesia, Spinal | 1 | 1999 | 23 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1999 | 43 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2001 | 839 | 0.010 |
Why?
|